Skip to main content
Year archive

Formycon AG — 2026 filings

All 19 regulatory filings released by Formycon AG (FYB) in 2026, sourced directly from the official regulator.

19 Filings
2026 Period
2026 filings (19)
Filing Released Lang
Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive and Baiama are now available in the European Union
Regulatory Filings
2026-05-19 English
Formycon AG: Bekanntmachung der Einberufung zur Hauptversammlung am 10.06.2026 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
Regulatory Filings
2026-05-04 German
Annual financial report 2025
Annual Report FY 2025
2026-04-23 English
Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
Earnings Release FY 2025
2026-04-22 English
Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
Report Publication Announcement
2026-04-20 English
Report Publication Announcement 2026
Report Publication Announcement
2026-04-16 English
Hinweis auf Jahresfinanzbericht vom 01.01.2025 bis zum 31.12.2025
Report Publication Announcement
2026-04-16 German
Hinweis auf Konzernabschluss vom 01.01.2025 bis zum 31.12.2025
Report Publication Announcement
2026-04-16 German
Hinweis auf Jahresfinanzbericht vom 01.01.2025 bis zum 31.12.2025
Report Publication Announcement
2026-04-16 German
Hinweis auf Konzernabschluss vom 01.01.2025 bis zum 31.12.2025
Report Publication Announcement
2026-04-16 German
Formycon AG:
Earnings Release FY 2025
2026-04-15 English
Ny rente - Attachment: Interests-2026-04-07.pdf
Interest Rate Update/Notice
2026-04-07 English
Ny rente
Interest Rate Update/Notice
2026-04-07 Norwegian Nynorsk
Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Report Publication Announcement
2026-03-18 English
Formycon AG publishes preliminary figures for the 2025 fiscal year
Earnings Release FY 2025
2026-03-04 English
Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab)
Regulatory Filings
2026-02-25 English
Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
Regulatory Filings
2026-02-11 English
Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
Director's Dealing
2026-01-14 English
Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
Director's Dealing
2026-01-13 English